Jazz reacquires rights in Americas for defibrotide

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) will reacquire from Sigma-Tau Group (Pomezia, Italy) rights in the Americas for defibrotide for $75 million up front. Sigma-Tau had rights to the product from Gentium S.p.A., which Jazz acquired. Sigma-Tau is eligible for a $25 million milestone payment upon FDA acceptance of an NDA for defibrotide to treat veno-occlusive disease (VOD) and up to an additional $150 million payment upon FDA approval. The deal is slated to close this quarter. Jazz was up $10.56 (11%) to $162.02 on Wednesday. ...